A synergistic antioxidant nanozyme platform for corneal neovascularization treatment.

Corneal neovascularization (CNV) is recognized as one of the most common blinding eye diseases, afflicting millions of individuals globally each year. Substantial evidence has demonstrated that oxidative stress and inflammation constitute pivotal pathogenic factors in the initiation and progression of CNV. In this study, we prepared a synergistic nanozyme platform for the antioxidant therapy of CNV. Specifically, we co-assembled manganese(iii) meso-tetra(4-carboxyphenyl)porphine (Mn-TCPP) with octahydrated zirconium(iv) chloride, followed by surface modification with platinum nanoparticles (Pt NPs), preparing the Pt NPs-Mn-TCPP@Zr (PMTZ) nanomedicine. The prepared PMTZ nanomedicine showed enhanced antioxidant performance, which could inhibit the migration of human umbilical vein epithelial cells and eliminate excessive reactive oxygen species produced by oxidative stress cells. Finally, PMTZ was applied in the treatment of CNV, and its therapeutic efficacy was confirmed through experimental validation.